51,012 Shares in Mirati Therapeutics Inc (MRTX) Acquired by Vident Investment Advisory LLC

Vident Investment Advisory LLC purchased a new stake in Mirati Therapeutics Inc (NASDAQ:MRTX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 51,012 shares of the biotechnology company’s stock, valued at approximately $2,515,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in MRTX. Schwab Charles Investment Management Inc. acquired a new position in Mirati Therapeutics in the 1st quarter valued at approximately $239,000. Northern Trust Corp increased its position in Mirati Therapeutics by 9.4% in the 1st quarter. Northern Trust Corp now owns 60,341 shares of the biotechnology company’s stock valued at $1,852,000 after acquiring an additional 5,197 shares during the period. BlackRock Inc. increased its position in Mirati Therapeutics by 24.3% in the 1st quarter. BlackRock Inc. now owns 634,234 shares of the biotechnology company’s stock valued at $19,472,000 after acquiring an additional 123,872 shares during the period. IFP Advisors Inc acquired a new position in Mirati Therapeutics in the 1st quarter valued at approximately $508,000. Finally, California Public Employees Retirement System acquired a new position in Mirati Therapeutics in the 1st quarter valued at approximately $275,000. Hedge funds and other institutional investors own 97.82% of the company’s stock.

Several equities analysts have issued reports on MRTX shares. Cann upped their price target on shares of Mirati Therapeutics from $35.00 to $62.00 and gave the company an “average” rating in a research report on Monday, July 9th. Citigroup upped their price target on shares of Mirati Therapeutics from $37.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, July 5th. Cowen restated a “buy” rating on shares of Mirati Therapeutics in a research report on Thursday, June 28th. SunTrust Banks upped their price target on shares of Mirati Therapeutics to $60.00 and gave the company a “buy” rating in a research report on Tuesday, June 19th. Finally, HC Wainwright upped their price target on shares of Mirati Therapeutics to $63.00 and gave the company a “buy” rating in a research report on Friday, July 20th. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $47.75.

In related news, SVP Jamie Christensen sold 10,207 shares of the stock in a transaction on Wednesday, June 27th. The shares were sold at an average price of $49.15, for a total transaction of $501,674.05. Following the transaction, the senior vice president now directly owns 8,085 shares of the company’s stock, valued at $397,377.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Charles M. Baum sold 51,810 shares of the stock in a transaction on Thursday, August 23rd. The stock was sold at an average price of $57.55, for a total transaction of $2,981,665.50. Following the transaction, the chief executive officer now directly owns 102,742 shares in the company, valued at $5,912,802.10. The disclosure for this sale can be found here. Corporate insiders own 4.86% of the company’s stock.

NASDAQ:MRTX opened at $55.30 on Friday. Mirati Therapeutics Inc has a 52 week low of $9.15 and a 52 week high of $65.35. The firm has a market capitalization of $1.78 billion, a PE ratio of -19.89 and a beta of 1.95.

Mirati Therapeutics (NASDAQ:MRTX) last posted its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.16). sell-side analysts anticipate that Mirati Therapeutics Inc will post -3.14 earnings per share for the current year.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC.

Read More: Outstanding Shares and The Effect on Share Price

Want to see what other hedge funds are holding MRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirati Therapeutics Inc (NASDAQ:MRTX).

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply